Advaxis Doses First Patient With Customized Immunotherapy Targeting Personal Neoantigens

Advaxis Doses First Patient With Customized Immunotherapy Targeting Personal Neoantigens

Submitted by CP Staff on June 11, 2018 - 9:37am
Source: 
CP Wire
News Tags: 
Advaxis
ADXS-NEO
immunotherapy
non-small cell lung cancer
clinical trials
Headline: 
Advaxis Doses First Patient With Customized Immunotherapy Targeting Personal Neoantigens
snippet: 
  •  Company just announced 24% cut in workforce
  • First patient is being treated for non-small cell lung cancer
  • ADXS-NEO generates T cell responses against neoantigen peptides that control tumor growth, even when they were identified as “non-immunogenic”

Do Not Allow Advertisers to Use My Personal information